The translation initiation factor eIF4E mediates a rate-limiting process that drives selective translation of many oncongenic proteins such as cyclin D1, survivin and VEGF, thereby contributing to tumour growth, metastasis and therapy resistance. As an essential regulatory hub in cancer signalling network, many oncogenic signalling pathways appear to converge on eIF4E. Therefore, targeting eIF4E-mediated cap-dependent translation is considered a promising anticancer strategy. This paper reviews the strategies that can be used to target eIF4E, highlighting agents that target eIF4E activity at each distinct level.
Introduction
Translation control, a tightly regulated process, plays a critical role in cell growth, proliferation and differentiation. Among the four consecutive stages of translation (initiation, elongation, termination and ribosome recycling), more attention was paid to initiation (Ref. 1) . At this stage, the 43S preinitiation ribosome complex is recruited to the 5 ′ terminus of mRNA through translation initiation complex eIF4F (Ref. 2) . eIF4F is a heterotrimer complex binding the 5 ′ -terminal cap structure 7-MeGpppN (N is any nucleotide). eIF4F consists of eIF4E, the 5 ′ cap mRNA-binding protein; eIF4A, an ATP-dependent helicase unwinding the secondary structure of mRNA; and eIF4G, a scaffolding molecule serving a docking function in the assembly of eIF4F complex (Ref. 3) . eIF4E mediates the association of eIF4F with cap structure and promotes recruitment of ribosome to the 5 ′ end of mRNA, playing a vital role in regulating global translation rates. The role of eIF4E in translation regulation unrelated to initiation, such as export of some specific mRNAs (e.g. cyclin D) from nucleus to cytoplasm (Refs 4, 5), has also been emphasised. Cellular mRNAs can be categorised into two groups according to their structure property and inherent 'translatability': strong mRNAs (e.g. housekeeping genes), which have relatively short, unstructured 5 ′ UTRs (less C + G content); and weak mRNAs, which have lengthy, highly structured 5 ′ UTRs (G + C rich) (Refs 6, 7). The significant difference between them is that weak mRNAs are much more dependent on eIF4E availability and poorly translated under normal conditions when eIF4F complex formation is limited. These mRNAs predominantly encode proteins including proto-oncogenes that regulate hallmark capabilities of cancer cells. When eIF4E is overexpressed or hyperactive, translation of weak mRNAs is selectively and disproportionately enhanced, while strong mRNAs are only minimally affected by alteration in eIF4F complex formation.
Several studies have demonstrated that elevated eIF4E levels preferentially increase mRNA translation involved in all aspects of malignancy, such as protooncoproteins (e.g. c-myc, cyclin D1, ODC, survivin), angiogenesis factors (e.g. FGF2 and VEGF) and degradative enzymes (e.g. MMP9) (Ref. 8) . The list of mRNAs controlled by eIF4E is ever-increasing. Moreover, increased eIF4E up-regulates the nucleocytoplasmic transport of mRNAs encoding potent growth and survival proteins, such as cyclin D1 (Ref. 9) . Therefore, eIF4E level affects transformation, tumourigenesis, metastasis, and drug resistance in both experimental cancer models and human cancer tissues. Indeed, its overexpression is common in multiple cancer types, including malignancies of prostate, breast, head and neck, stomach, colon, lung, skin, oesophagus, bladder, cervix and the hematopoietic system (Refs 10, 11). Also, elevated eIF4E levels may serve as a biomarker predicting disease progression, overall survival, or relapse after definitive therapy (Refs 12, 13) . On the contrary, knockdown eIF4E by small interfering RNA (siRNA) can suppress oncogenic transformation (Refs 14, 15, 16) .
The activation of eIF4E, which functions as a regulatory hub of many major oncogenic pathways, is a crucial event of the PI3K/AKT/mTOR pathway. Consequently, it has attracted considerable attention as a promising target for anticancer drug discovery in practice (Ref. 7) . This review provides a comprehensive overview of strategies applicable for developing eIF4E-targeted agents. eIF4E regulation and targeting strategies eIF4E is regulated at multiple levels, including gene expression, sequestration and phosphorylation, etc. (Refs 17) .
At the transcriptional level, Myc is one of the best known transcription factors, which can activate eIF4E gene through two Myc-binding sites (E-boxes) in the eIF4E promoter (Ref. 7). At post-transcriptional level, HuR, a transcriptional factor, is responsible for stabilising eIF4E mRNA (Ref. 18 ). Post-translationally, eIF4E can be ubiquitinated primarily at Lys-159 and go through proteasome-dependent degradation (Ref. 19) .
The interaction of eIF4E with eIF4 G is indispensible for cap-dependent translation initiation. A group of factors generally known as eIF4E inhibitory proteins modulate the eIF4E-eIF4G interaction (Ref. 20) . The most well-studied eIF4E inhibitory proteins are 4EBPs, which sequester free-state eIF4E from eIF4G and block eIF4F complex formation. This sequestration results in the repression of translation of certain mRNAs that normally require high levels of available eIF4E (Ref. 20) . Upon nutrients, energy, growth factors and stress stimulation, 4EBPs become phosphorylated at different sites as a consequence of the activation of PI3 K/AKT/mTOR signalling pathways. 4E-BP1 is one of the direct substrates of mTOR Complex 1 (mTORC1). Phosphorylated 4E-BP1 releases eIF4E, which is then free to associate with eIF4G to stimulate translation initiation (Refs 21, 22) . Besides 4EBPs, the newly discovered eIF4E inhibitory proteins (e.g. Maskin and Cup) associate with eIF4E only on specific mRNAs through interactions with RNA-binding proteins (Ref. 20) .
In addition, eIF4E itself has been shown to be phosphorylated in cancer cells, which is a prerequisite for the activity of eIF4E in cancer cells, whereas dispensable for normal development (Ref. 23 ). Thus, an increased level of phosphorylated eIF4E was found in a broad spectrum of cancer cell lines (Ref. 24) . Phosphorylation of eIF4E (Ser209) is mediated by the MAP kinase-interacting protein kinases (Mnk1 and Mnk2), which are in turn activated by ERK and p38 MAPK pathways (Refs 25, 26) .
Till now, eIF4E-targeted strategies should include: targeting eIF4E synthesis; targeting eIF4F complex integrity (antagonising eIF4E-to-cap and eIF4E-eIF4 G interaction); sequestration of eIF4E and phosphorylations of eIF4E. A summary of the strategies are shown in Figures 1 and 2 . Therapeutic agents derived from these strategies that have been developed are summarised in Figure 3 and Table 1 While effective in mammalian cell-free systems and zebrafish embryos, the efficacy of 7-BnGMP in cells is poor because of its low cell-membrane permeability. One approach to improve its in vivo activity is to develop a stable, cell-permeable prodrug (pro-nucleotide) which can be bio-activated within cells 
Targeting eIF4E and eIF4G interaction
Studies have demonstrated that, eIF4E function is also regulated at the level of interactions with eIF4G and 4E-BPs (Ref. 20) . This occurs on the dorsal surface of eIF4E, opposite to the cap-binding site. Binding of eIF4 G to eIF4E improves cap-dependent translation through recruitment of eIF4A and the eIF3-40S Although 4EGI-1 was discovered as a small molecule inhibitor that disturbed the interaction of eIF4E and eIF4G, Fan et al. revealed that 4EGI-1 sensitised human lung cancer cells by promoting TRAILmediated apoptosis (Refs 126, 127 ). In addition, cancer cells showed only 2-fold higher susceptibility to 4EGI-1 than their non-transformed counterparts. 
Sequestering eIF4E
4EBP mimetic peptides directly binding eIF4E As mentioned above, 4EBP sequesters eIF4E and consequently prevents cap-dependent translation initiation. Reasonably, 4EBP mimetic peptides which directly bind with eIF4E can reduce free eIF4E level, just as 4EBPs do. Recently, a strategy developed by Naora and coworkers is to use 4EBP-based peptides to sequester eIF4E (Ref. 48). They designed a peptide containing residues 49-68 of 4EBP1, and fused it to an analogue of gonadotropin-releasing hormone (GnRH). GnRH agonist-4EBP fusion peptide efficiently repressed the growth of GnRH receptor-expressing tumour cells, but not receptor negative cells, which is suitable for a targeted strategy. Therefore, GnRH-4EBP fusion peptide has the potential to treat ovarian cancer because this kind of cancer is hardly cured by conventional chemotherapies.
In addition, a eukaryotic expression vector pSecXt4EBP1 was skilfully constructed, which contained phosphorylation defective 4E-BP1 domain and the protein transduction domain. The former domain down-regulated the expression of eIF4E by direct binding, and the latter domain can help plasmid penetrate the cellular membrane and enhance the efficiency of vector's spread. Interestingly enough, this plasmid significantly down-regulated tumour growth and improved the radiosensitivity of mouse breast carcinoma allografts in BALB/C mice model (Ref. 
Rapamycin and Rapalogues
In general, normalising deregulated eIF4F-mediated translation can be accomplished indirectly by interrupting upstream signals leading to eIF4E dissociation from 4EBPs. Naturally, targeting mTOR signalling pathway is a therapeutically attractive option for the purpose of sequestering eIF4E because 4EBPs are direct substrates of mTOR kinase (Ref. 130) .
So far, rapamycin (sirolimus) and its analogues are the most well characterised mTOR inhibitors. As an immunosuppresive drug, rapamycin can also act as a cytostatic agent, preventing growth of various tumour cell lines including renal cancer, small cell lung cancer, and pancreatic cancer cells (Refs 51, 52, 53). One potential mechanism explaining its antiproliferative effects is the prevention of phosphorylation of 4E-BP1 by mTORC1, which in turn sequesters eIF4E and restrains the initiation of cap-dependent translation (Ref. 54).
Although rapamycin has shown promising antitumour effects in several experimental tumour models, its clinical trials as an anticancer drug is unsuccessful at present. 
Second-generation mTOR inhibitors
Extensive research on mTOR has uncovered a complex network of regulatory loops that impact on mTOR-targeting approaches (Ref. 133 ) and may explain the inherent limitations of rapamycin-based strategies. For example, when mTORC1 is inhibited and unable to activate S6K, S6K-mediated feedback loop can lead to an up-regulation of PI3K signalling, and provide pro-survival and proliferative signals through Akt (Ref. 134 ). These loops, at least in some degree, counteract the effects of rapamycin in experimental cancer models and in patients (Ref. 133) . Moreover, because mTORC2 also plays a vital role in tumourigenesis (Ref. 135) , the high selectivity of rapamycin for mTORC1 (Refs 136, 137) really triggers a major concern. Thirdly, rapamycin does not inhibit 4EBP phosphorylation by mTOR in some cells. One explanation of this is that it works through sterically blocking mTOR access to substrates, which is inefficient for a small substrate like 4EBP, while very efficient for large ones like S6K1 (Refs 138, 139, 140 ). All the drawbacks mentioned above indicate that there exists an urgent need to search for second-generation mTOR inhibitors, which can sequester eIF4E more efficiently.
The second-generation inhibitors, which bind to the catalytic sites of mTOR, inhibit kinase activities of both mTORC1 and mTORC2 (Refs 68, 69, 70, 73, 74, 75, 76) . The active-site inhibitors of mTOR, PP242 and PP30, suppressed proliferation of primary cells more potently than rapamycin (Ref. 68). Torin1, another highly potent and selective ATP-competitive mTOR inhibitor, impaired cell growth and proliferation to a far greater extent than rapamycin (Ref. 
Targeting eIF4E phosphorylation
Role of Mnks in tumourigenesis and its regulation Although some success has been achieved on the inhibition of PI3 K/mTOR axis, the multiple feedback loops make this pathway disappointing, to some degree. The ideal goal should be to down-regulate the function of specific pathway in cancer cells without affecting normal cells and eliciting feedback loops that could impair the therapeutic efficacy. Phosphorylation of eIF4E by Mnks on Ser209 is critical for oncogenic activity of eIF4E (Refs 141, 142) Therefore, eIF4E phosphorylation has been estab- 
Mnk inhibitors
So far, three well-studied Mnk inhibitors have been reported: CGP052088, CGP57380 and Cercosporamide.
CGP052088 is a derivative of staurosporine, a broadspectrum kinase inhibitor. It inhibited Mnk1 with an IC50 value of 70 nM in biochemical assays and was cytotoxic with a GI50 value of 4.5 μM in a 24 h-MTT proliferation assay (Ref. 
Conclusions and outlook
Our understanding of human cancer as a multi-factornetwork disease has led to the development of nextgeneration therapeutics. It is clear now that targeting regulatory hubs in the cancer signalling network instead of targeting individual genetic alterations will be more effective in treating a very heterogenous tumour. Accumulating evidences indicate that one of such hubs is eIF4E, serving as a node on which multiple oncogenic signalling pathways converge. As a result, eIF4E and translation initiation provide a promising target for cancer therapeutics. Indeed, enthusiasm for developing small molecule inhibitors blocking eIF4E function has lasted over the years.
In addition to the therapeutic strategies targeting eIF4E aforementioned, some other components of eIF4F complex should be considered as appealing oncology drug targets. These include eIF4A, an RNA helicase, which is frequently activated in cancer cells, either by its overexpression or by repression of the tumour suppressor Pdcd4 (programmed cell death 4) (Ref. 152) . Silvesterol and Pateamine A are both eIF4A inhibitors. Silvesterol can effectively modulate the activity of eIF4A and repress translation initiation, exhibiting powerful anticancer activity in human breast cancer and prostate cancer xenograft models by inducing apoptosis and inhibiting angiogenesis (Refs 92, 93) . In addition, the suppressive effects of Pateamine A (PatA) on translation are mediated through increasing the RNA-binding affinity of free eIF4A, thus sequestering eIF4A from the 4F complex, which may lead to stalling of initiation complexes (Ref. 94) .
The binding of initiator tRNA to the 40S ribosomal unit is mediated by translation initiation factor 2 (eIF2). Phosphorylation of α-subunit of eIF2 prevents formation of the eIF2/GTP/Met-tRNA complex and stops global protein synthesis (Ref. 153) . As a consequence, eIF2 is also a promising drug target at the level of translation initiation. eIF2α can be phosphorylated by haeme-regulated inhibitor, PERK/PEK, and the double-stranded RNA-activated protein kinase (PKR) (Ref. 
